[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Monday Afternoon",
    "summary": "Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the",
    "url": "https://finnhub.io/api/news?id=9f2a1731967f9be71c3d8da809f7f4fbce655acc80558f7f511bf725bbbd245f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744654081,
      "headline": "Sector Update: Health Care Stocks Rise Monday Afternoon",
      "id": 133917817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the",
      "url": "https://finnhub.io/api/news?id=9f2a1731967f9be71c3d8da809f7f4fbce655acc80558f7f511bf725bbbd245f"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 500-point rally highlighted by gains in shares of Apple, Amgen",
    "summary": "Dow's 500-point rally highlighted by gains in shares of Apple, Amgen",
    "url": "https://finnhub.io/api/news?id=35252498fb89524b2fa5e9031aad0ad355981e09c7b36d73032de3f1e00f4416",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744644240,
      "headline": "Dow's 500-point rally highlighted by gains in shares of Apple, Amgen",
      "id": 133911631,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's 500-point rally highlighted by gains in shares of Apple, Amgen",
      "url": "https://finnhub.io/api/news?id=35252498fb89524b2fa5e9031aad0ad355981e09c7b36d73032de3f1e00f4416"
    }
  },
  {
    "ts": null,
    "headline": "This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.",
    "summary": "This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.",
    "url": "https://finnhub.io/api/news?id=c66e6b6197c3cc7bb18fbdd1bef486175ff7348ee62876c94aad8298722bd614",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744637220,
      "headline": "This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.",
      "id": 134146423,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.",
      "url": "https://finnhub.io/api/news?id=c66e6b6197c3cc7bb18fbdd1bef486175ff7348ee62876c94aad8298722bd614"
    }
  },
  {
    "ts": null,
    "headline": "Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit",
    "summary": "Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.",
    "url": "https://finnhub.io/api/news?id=b5bb9afc9dc53645bc72324b99635d54d05fa546d53f2032097f156f6de5306a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744628367,
      "headline": "Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit",
      "id": 133908340,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.",
      "url": "https://finnhub.io/api/news?id=b5bb9afc9dc53645bc72324b99635d54d05fa546d53f2032097f156f6de5306a"
    }
  },
  {
    "ts": null,
    "headline": "Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC",
    "summary": "The randomised, controlled study aims to assess the therapy’s safety and efficacy.",
    "url": "https://finnhub.io/api/news?id=703022b0d2845fea62424b059428045665e0b4835b06df4881e360b5cdd9868f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744622836,
      "headline": "Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC",
      "id": 133908341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The randomised, controlled study aims to assess the therapy’s safety and efficacy.",
      "url": "https://finnhub.io/api/news?id=703022b0d2845fea62424b059428045665e0b4835b06df4881e360b5cdd9868f"
    }
  },
  {
    "ts": null,
    "headline": "Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug",
    "summary": "ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of its blockbuster medicine, Enbrel (etanercept).  Sandoz alleges Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi, by unlawfully purchasing and using certain patent rights to entrench its dominant market position.  Amgen said it did not comment on pending litigation.",
    "url": "https://finnhub.io/api/news?id=50c146d59d76784f382de0823ce931c6ed9cd4abecf80a9679956065c673d519",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744607533,
      "headline": "Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug",
      "id": 133908342,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of its blockbuster medicine, Enbrel (etanercept).  Sandoz alleges Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi, by unlawfully purchasing and using certain patent rights to entrench its dominant market position.  Amgen said it did not comment on pending litigation.",
      "url": "https://finnhub.io/api/news?id=50c146d59d76784f382de0823ce931c6ed9cd4abecf80a9679956065c673d519"
    }
  },
  {
    "ts": null,
    "headline": "Switzerland's Sandoz files antitrust lawsuit against Amgen in US",
    "summary": "Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel . ...",
    "url": "https://finnhub.io/api/news?id=b55b5fb65c8f0d0fca0dec02f64fe6796d6392cdbb32f23450e21a47396e4822",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744593133,
      "headline": "Switzerland's Sandoz files antitrust lawsuit against Amgen in US",
      "id": 133903737,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel . ...",
      "url": "https://finnhub.io/api/news?id=b55b5fb65c8f0d0fca0dec02f64fe6796d6392cdbb32f23450e21a47396e4822"
    }
  }
]